PVLA Palvella Therapeutics, Inc.

QT82

Latest market price

150.69

+4.36+2.98%

Overview Short InterestFilings

PVLAQT82Palvella Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

150.69+2.98%

Earnings

Up 3.0% — Earnings due 2026-11-05 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

BCRX+0.67%$8.30 LKFT+0.47%$32.17 ZYME+2.00%$29.57 VCEL+0.11%$40.56 AUPH+1.05%$16.31 VERA-0.10%$30.25 SEPN+1.17%$43.70 XNCR+1.45%$30.09

Snapshot

Index	—	P/E	—	EPS (ttm)	-4.83	Insider Own	13.07%	Shs Outstand	14.41M	Perf Week	15.92%

Market Cap	2.11B	Forward P/E	—	EPS next Y	-8.29	Insider Trans	-4.31%	Shs Float	9.16M	Perf Month	10.46%

Enterprise Value	1.86B	PEG	—	EPS next Q	-1.78			Short Float	26.28%	Perf Quarter	-3.72%

Income	-62.00M	P/S	—	EPS this Y	—			Short Ratio	11.33	Perf Half Y	14.67%

Sales	0.00	P/B	9.72	EPS next Y	—	ROA	-24.34%	Short Interest	2.41M	Perf YTD	39.80%

Book/sh	15.06	P/C	8.40	EPS next 5Y	—	ROE	-47.84%	52W High	161.38 -6.62%	Perf Year	86.60%

Cash/sh	17.42	P/FCF	—	EPS past 3/5Y	—	ROIC	-23.88%	52W Low	71.55 110.61%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	6.87% 5.54%	Perf 5Y	—

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	7.51	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	21.18	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	59.68	Recom	1.91

Dividend Gr. 3/5Y	—	Current Ratio	21.18	EPS Q/Q	-76.74%	SMA20	10.96%	Beta	1.74	Target Price	228.50

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	—	SMA50	3.37%	Rel Volume	1.40	Prev Close	146.33

Employees	29	LT Debt/Eq	0.00	Earnings	Nov 05	SMA200	15.09%	Avg Volume	216.17K	Price	150.69

IPO Date	Jan 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-29.55% —	Net Debt/EBITDA	—	Volume	303,458	Change	2.98%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-16-26	Reiterated	Raymond James	Strong Buy	$193 → $226
Oct-12-26	Reiterated	HC Wainwright & Co.	Buy	$270 → $246
Sep-21-26	Reiterated	Chardan Capital	Buy	$210 → $240
Aug-05-26	Reiterated	Truist Financial	Buy	$210 → $207
Aug-05-26	Reiterated	Canaccord Genuity	Buy	$227 → $232
Jul-22-26	Reiterated	H.C. Wainwright	Buy	$255 → $270
May-12-26	Initiated	Stephens	Overweight	$220
Feb-24-26	Reiterated	Truist Financial	Buy	$190 → $210
Feb-24-26	Reiterated	Stifel Nicolaus		$180 → $250
Feb-24-26	Reiterated	Chardan Capital	Buy	$174 → $210

Latest News· Times ET

Today

Today07:30AM

Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conferenceglobenewswire.com

Oct-29-26

Oct-29-2607:30AM

Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026globenewswire.com

Oct-28-26

Oct-28-2607:30AM

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date SetYahoo

Oct-25-26

Oct-25-2602:07AM

Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expandsmarketbeat.com

Oct-22-26

Oct-22-2604:01PM

Ligand to Host Investor Day on December 8, 2026Yahoo

Oct-16-26

Oct-16-2606:40AM

William Blair Initiates Coverage On Palvella Therapeutics with Outperform RatingBenzinga

Oct-15-26

Oct-15-2607:30AM

Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conferenceglobenewswire.com

Oct-13-26

Oct-13-2607:30AM

Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conferenceglobenewswire.com

Oct-12-26

Oct-12-2604:19AM

Amazon To $310? Here Are 10 Top Analyst Forecasts For MondayBenzinga

Sep-29-26

Sep-29-2611:52AM

Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Strongerseekingalpha.com

Sep-28-26

Sep-28-2607:30AM

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformationsglobenewswire.com

Sep-09-26

Sep-09-2607:30AM

Palvella Therapeutics Appoints James R. Treat, M.D.globenewswire.com

07:30AM

Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical OfficerYahoo

Sep-02-26

Sep-02-2607:30AM

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferencesglobenewswire.com

Aug-31-26

Aug-31-2607:30AM

Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformationsglobenewswire.com

Company

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021
Total Revenue	0	0	0	0	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—
Gross Profit	0	0	0	0	—	—
Selling, General and Administrative Excl. Other	23	16	6	3	—	—
Research and Development	35	23	8	9	—	—
Other Operating Expense	-1	0	0	0	—	—
Operating Income	-57	-39	-14	-12	—	—
Interest Expense	8	6	4	0	—	—
Unusual Expense	—	—	—	—	—	—
Non-Operating Income (Expense)	3	3	1	31	—	—
Net Income Before Taxes	-62	-42	-17	19	—	—
Income Taxes	0	0	0	0	—	—
Consolidated Net Income	-62	-42	-17	19	—	—
Net Income From Continuing Operations	-62	-42	-17	19	—	—
Net Income	-62	-42	-17	19	—	—
EPS (Recurring)	-4.83	-3.71	-7.83	14.74	—	—
EPS (Basic, Before Extraordinaries)	-4.83	-3.71	-7.83	14.74	—	—
EPS (Diluted)	-4.83	-3.71	-7.83	14.74	—	—
EBITDA	-51	-36	-13	19	—	—
Other After Tax Adjustments	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—
Shares Outstanding	14	11	2	1	—	—
Market Capitalization	2,110	1,151	24	—	—	—
Operating Lease Expense	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goin Kathleen	Chief Operating Officer	Oct 21 '26	Sale	124.58	4,313	537,308	0	Oct 23
Goin Kathleen	Chief Operating Officer	Oct 21 '26	Option Exercise	8.11	4,313	34,962	4,313	Oct 23
JENKINS GEORGE M	Director	Oct 14 '26	Sale	123.49	7,174	885,913	132,616	Oct 14
JENKINS GEORGE M	Director	Oct 13 '26	Sale	130.36	7,174	935,231	139,790	Oct 14
JENKINS GEORGE M	Director	Oct 12 '26	Sale	133.69	13,152	1,758,330	146,964	Oct 14
Goin Kathleen	Chief Operating Officer	Sep 16 '26	Option Exercise	8.11	4,302	34,884	4,302	Sep 18
Goin Kathleen	Chief Operating Officer	Sep 16 '26	Sale	152.24	4,302	654,924	0	Sep 18
JENKINS GEORGE M	Director	Sep 15 '26	Sale	150.14	1,777	266,806	160,116	Sep 15
JENKINS GEORGE M	Director	Sep 14 '26	Sale	151.96	13,352	2,028,905	161,893	Sep 15
JENKINS GEORGE M	Director	Sep 11 '26	Sale	151.28	12,371	1,871,435	175,245	Sep 15
KIRITSY CHRISTOPHER P	Director	Sep 02 '26	Option Exercise	127.20	313	39,814	563	Sep 04
KIRITSY CHRISTOPHER P	Director	Sep 02 '26	Sale	157.00	313	49,141	250	Sep 04
Goin Kathleen	Chief Operating Officer	Aug 19 '26	Option Exercise	8.11	4,302	34,884	4,302	Aug 20
Goin Kathleen	Chief Operating Officer	Aug 19 '26	Sale	152.21	4,302	654,791	0	Aug 20
Goin Kathleen	Chief Operating Officer	Jul 15 '26	Option Exercise	8.11	4,302	34,884	4,302	Jul 17

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.